• Qlife published its interim report for Q2 2026 (April–June), reporting revenue of kSEK 728, mainly from a contracted feasibility study.
• EBITDA was kSEK -4,720. Net loss totaled kSEK -4,978. Total cash flow was kSEK -2,617.
• Entered a fully funded feasibility agreement with a global pharma company to test a biomarker application on Egoo Health.
• Report posted at https://qlifeholding.com/en/investors/finansiella-rapporter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.